Category Archives: Neurotechnology

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland--(BUSINESS WIRE)--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces it has completed enrollment in the Up-LIFT study, a pivotal trial to evaluate the safety and effectiveness of ARC Therapy to restore hand and arm function in people with spinal cord injury (SCI). Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology.

ONWARD has now reached the studys enrollment ceiling of 65 subjects, enrolled at 14 leading SCI research sites throughout the United States, Canada, the United Kingdom, and the Netherlands. The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) to treat upper extremity functional deficits in people with chronic tetraplegia.

The study reached its enrollment objective in under 12 months despite lock-downs, travel restrictions, and other COVID-related challenges, said Dave Marver, Chief Executive Officer of ONWARD. This milestone underscores the SCI communitys enthusiasm for this promising therapy. We will now work with determination to prepare submissions to regulatory authorities in the US and Europe so we can bring this important therapy to market for the benefit of people with SCI and their loved ones.

For individuals with impaired arm and hand function due to spinal cord injury, improved hand function directly translates into meaningful gains in terms of quality of life - being able to eat, dress or perform other daily life activities, said Edelle Field-Fote, PT, PhD, FAPTA, FASIA, co-PI of the Up-LIFT trial and Director of Spinal Cord Injury Research at Shepherd Center and Professor of Rehabilitation Medicine at Emory University School of Medicine. It was very rewarding to take part in this important trial and collaborate with many of the most highly respected SCI rehabilitation centers across the globe.

The end of enrollment for this trial marks a significant milestone in bringing non-invasive stimulation for restoring hand and arm function to people living with spinal cord injury said Chet Moritz, PhD, co-PI of the Up-LIFT trial and Associate Professor in the Departments of Electrical & Computer Engineering and Rehabilitation Medicine at the University of Washington in Seattle. We are hopeful this study can lead to the broad availability of this important therapy.

The company expects to initially commercialize ARC Therapy in the US, Germany, France, UK, Switzerland, and the Netherlands. To learn more about ONWARDs ARC Therapy and the companys vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories. ONWARDs ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The companys first FDA pivotal trial, called Up-LIFT, commenced in January 2021 and has now completed enrollment with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.

About Dr. Edelle Field-Fote

Dr. Edelle Field-Fote has a 20+ years of SCI research, building on her clinical background as a physical therapist and Ph.D. training in an animal model of SCI. Her contributions to SCI literature include the largest study to date of locomotor training for persons with chronic, motor-incomplete SCI, as well as the first-ever study of a rehabilitation intervention to promote neuroplasticity for improved hand function in persons with tetraplegia. Dr. Field-Fotes research has been funded by the National Institutes of Health (NIH) since 1997, and also by the National Institute on Independent Living, Disability and Rehabilitation Research (NILDRR) and the Department of Defense (DoD). Dr. Field-Fote is the editor/author of the textbook Spinal Cord Injury Rehabilitation (FA Davis Publishers).

About Dr. Chet Moritz

Dr. Chet Moritz is Associate Professor in the departments of Electrical & Computer Engineering, Rehabilitation Medicine, and Physiology & Biophysics at University of Washington, Seatlle. He was named an Allen Distinguished Investigator and appointed to the Christopher & Dana Reeve International Consortium on Spinal Cord Repair. Chet serves as the Co-Director for the Center for Neurotechnology, an NSF Engineering Research Center (ERC). Chet directs the Restorative Technologies Laboratory (RTL) which focuses on developing technologies to treat paralysis due to spinal cord injury. Current research in the lab includes a multi-site clinical trial of spinal stimulation to restore hand function for people with spinal cord injury, stimulation to improve walking for children with cerebral palsy, and optogenetic stimulation to guide neuroplasticity and recovery in the injured spinal cord of animals.

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Visit link:

ONWARD Announces Completion of Enrollment in the Up-LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury - Business Wire

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have identified brain signals associated with obsessive compulsive disorder symptoms, paving the way for adaptive treatment.

The researchers recorded electrical signals in the human brain associated with ebbs and flows in OCD symptoms over an extended period in participants homes as they went about daily living.

The research could be an important step in making an emerging therapy called deep brain stimulation responsive to everyday changes in OCD symptoms.

OCD, which affects as much as 2% of the worlds population, causes recurring unwanted thoughts and repetitive behaviors. The disorder is often debilitating, and up to 20-40% of cases dont respond to traditional drug or behavioral treatments.

Deep brain stimulation, a technique that involves small electrodes precisely placed in the brain that deliver mild electrical pulses, is effective in treating over half of patients for whom other therapies failed. A limitation is that DBS is unable to adjust to moment-to-moment changes in OCD symptoms, which the physical and social environment affect. But adaptive DBSwhich can adjust the intensity of stimulation in response to real-time signals recorded in the braincould be more effective than traditional DBS and reduce unwanted side effects.

OCD is a disorder in which symptom severity is highly variable over time and can be elicited by triggers in the environment, says David Borton, an associate professor of biomedical engineering at Brown University, a biomedical engineer at the US Department of Veterans Affairs Center for Neurorestoration and Neurotechnology, and a senior author of the new research.

A DBS system that can adjust stimulation intensity in response to symptoms may provide more relief and fewer side effects for patients. But in order to enable that technology, we must first identify the biomarkers in the brain associated with OCD symptoms, and that is what we are working to do in this study.

For the study, the researchers recruited five participants with severe OCD who were eligible for DBS treatment. Sameer Sheth of Baylor College of Medicine, lead neurosurgeon, implanted each participant with an investigational DBS device from Medtronic capable of both delivering stimulation and recording native electrical brain signals. Using the sensing capabilities of the hardware, the team gathered brain-signal data from participants in both clinical settings and at home as they went about daily activities.

Along with the brain signal data, the team also collected a suite of behavioral biomarkers. In the clinical setting, these included facial expression and body movement. Using computer vision and machine learning, they discovered that the behavioral features were associated with changes in internal brain states. At home, they measured participants self-reports of OCD symptom intensity as well as biometric dataheart rate and general activity levelsrecorded by a smart watch and paired smartphone application provided by Rune Labs. All of those behavioral measures were then time-synched to the brain-sensing data, enabling the researchers to look for correlations between the two.

This is the first time brain signals from participants with neuropsychiatric illness have been recorded chronically at home alongside relevant behavioral measures, says Nicole Provenza, a recent Brown University biomedical engineering PhD graduate from Bortons laboratory. Using these brain signals, we may be able to differentiate between when someone is experiencing OCD symptoms, and when they are not, and this technique made it possible to record this diversity of behavior and brain activity.

Provenzas analysis of the data showed that the technique did pick out brain-signal patterns potentially linked to OCD symptom fluctuation. While more work needs to be done across a larger cohort, this initial study shows that this technique is a promising way forward in confirming candidate biomarkers of OCD.

We were able to collect a far richer dataset than has been collected before, and we found some tantalizing trends that wed like to explore in a larger cohort of patients, Borton says. Now we know that we have the toolset to nail down control signals that could be used to adjust stimulation level according to peoples symptoms.

Once those biomarkers are positively identified, they could then be used in an adaptive DBS system. Currently, DBS systems employ a constant level of stimulation, which can be adjusted by a clinician at clinical visits. Adaptive DBS systems, in contrast, would stimulate and record brain activity and behavior continuously without the need to come to the clinic. When the system detects signals associated with an increase in symptom severity, it could ramp up stimulation to potentially provide additional relief. Likewise, stimulation could be toned down when symptoms abate. Such a system could potentially improve DBS therapy while reducing side effects.

In addition to advancing DBS therapy for cases of severe and treatment resistant OCD, this study has the potential for improving our understanding of the underlying neurocircuitry of the disorder, says Wayne Goodman of Baylor College of Medicine. This deepened understanding may allow us to identify new anatomic targets for treatment that may be amenable to novel interventions that are less invasive than DBS.

Work on this line of research is ongoing. Because OCD is a complex disorder than manifests itself in highly variable ways across patients, the team hopes to expand the number of participants to capture more of that variability. They seek to identify a fuller set of OCD biomarkers that could be used to guide adaptive DBS systems. Once those biomarkers are in place, the team hopes to work with device-makers to implement their DBS devices.

Our goal is to understand what those brain recordings are telling us and to train the device to recognize certain patterns associated with specific symptoms, Sheth says. The better we understand the neural signatures of health and disease, the greater our chances of using DBS to successfully treat challenging brain disorders like OCD.

The study appears in Nature Medicine. Additional researchers from the University of Pittsburgh and Carnegie Mellon University contributed to the work.

Support for the research came from the National Institutes of Healths BRAIN Initiative, the Charles Stark Draper Laboratory Fellowship, the McNair Foundation, the Texas Higher Education Coordinating Board, the National Institutes of Health, and the Karen T. Romer Undergraduate Teaching and Research Award at Brown University.

Source: Brown University

Read the rest here:

Team pinpoints brain signals tied to OCD symptoms - Futurity: Research News

PROVIDENCE, R.I. [Brown University] In an effort to improve treatment for obsessive compulsive disorder, a team of researchers has for the first time recorded electrical signals in the human brain associated with ebbs and flows in OCD symptoms over an extended period in their homes as they went about daily living. The research could be an important step in making an emerging therapy called deep brain stimulation responsive to everyday changes in OCD symptoms.

OCD, which affects as much as 2% of the worlds population, causes recurring unwanted thoughts and repetitive behaviors. The disorder is often debilitating, and up to 20-40% of cases dont respond to traditional drug or behavioral treatments. Deep brain stimulation, a technique that involves small electrodes precisely placed in the brain that deliver mild electrical pulses, is effective in treating over half of patients for whom other therapies failed. A limitation is that DBS is unable to adjust to moment-to-moment changes in OCD symptom, which are impacted by the physical and social environment . But adaptive DBS which can adjust the intensity of stimulation in response to real-time signals recorded in the brain could be more effective than traditional DBS and reduce unwanted side effects.

OCD is a disorder in which symptom severity is highly variable over time and can be elicited by triggers in theenvironment, said David Borton, an associate professor of biomedical engineering at Brown University, a biomedical engineer at the U.S. Department of Veterans Affairs Center for Neurorestoration and Neurotechnology and a senior author of the new research. A DBS system that can adjust stimulation intensity in response to symptoms may provide more relief and fewer side effects for patients. But in order to enable that technology, we must first identify the biomarkers in the brain associated with OCD symptoms, and that is what we are working to do in this study.

The research, led by Nicole Provenza, a recent Brown biomedical engineering Ph.D. graduate from Bortons laboratory, was a collaboration between Bortons research group, affiliated with Browns Carney Institute for Brain Science and School of Engineering; Dr. Wayne Goodmans and Dr. Sameer Sheths research groups at Baylor College of Medicine; and Jeff Cohn from the University of Pittsburghs Department of Psychology and Intelligent Systems Program and Carnegie Mellon University.

For the study, Goodmans team recruited five participants with severe OCD who were eligible for DBS treatment. Sheth, lead neurosurgeon, implanted each participant with an investigational DBS device from Medtronic capable of both delivering stimulation and recording native electrical brain signals. Using the sensing capabilities of the hardware, the team gathered brain-signal data from participants in both clinical settings and at home as they went about daily activities.

Along with the brain signal data, the team also collected a suite of behavioral biomarkers. In the clinical setting, these included facial expression and body movement. Using computer vision and machine learning, they discovered that the behavioral features were associated with changes in internal brain states. At home, they measured participants self-reports of OCD symptom intensity as well as biometric data heart rate and general activity levels recorded by a smart watch and paired smartphone application provided by Rune Labs. All of those behavioral measures were then time-synched to the brain-sensing data, enabling the researchers to look for correlations between the two.

This is the first time brain signals from participants with neuropsychiatric illness have been recorded chronically at home alongside relevant behavioral measures, Provenza said. Using these brain signals, we may be able to differentiate between when someone is experiencing OCD symptoms, and when they are not, and this technique made it possible to record this diversity of behavior and brain activity.

Provenzas analysis of the data showed that the technique did pick out brain-signal patterns potentially linked to OCD symptom fluctuation. While more work needs to be done across a larger cohort, this initial study shows that this technique is a promising way forward in confirming candidate biomarkers of OCD.

We were able to collect a far richer dataset than has been collected before, and we found some tantalizing trends that wed like to explore in a larger cohort of patients, Borton said. Now we know that we have the toolset to nail down control signals that could be used to adjust stimulation level according to people's symptoms.

Once those biomarkers are positively identified, they could then be used in an adaptive DBS system. Currently, DBS systems employ a constant level of stimulation, which can be adjusted by a clinician at clinical visits. Adaptive DBS systems, in contrast, would stimulate and record brain activity and behavior continuously without the need to come to the clinic. When the system detects signals associated with an increase in symptom severity, it could ramp up stimulation to potentially provide additional relief. Likewise, stimulation could be toned down when symptoms abate. Such a system could potentially improve DBS therapy while reducing side effects.

In addition to advancing DBS therapy for cases of severe and treatment resistant OCD, this study has the potential for improving our understanding of the underlying neurocircuitry of the disorder, Goodman said. This deepened understanding may allow us to identify new anatomic targets for treatment that may be amenable to novel interventions that are less invasive than DBS.

Work on this line of research is ongoing. Because OCD is a complex disorder than manifests itself in highly variable ways across patients, the team hopes to expand the number of participants to capture more of that variability. They seek to identify a fuller set of OCD biomarkers that could be used to guide adaptive DBS systems. Once those biomarkers are in place, the team hopes to work with device-makers to implement their DBS devices.

Our goal is to understand what those brain recordings are telling us and to train the device to recognize certain patterns associated with specific symptoms, Sheth said. The better we understand the neural signatures of health and disease, the greater our chances of using DBS to successfully treat challenging brain disorders like OCD.

The research was supported by the National Institutes of Healths BRAIN Initiative (UH3NS100549 and UH3NS103549), the Charles Stark Draper Laboratory Fellowship, the McNair Foundation, the Texas Higher Education Coordinating Board, the National Institutes of Health (1RF1MH121371, U54-HD083092, NIH MH096951, K01-MH-116364 and R21-NS-104953, 3R25MH101076-05S2, 1S10OD025181) and the Karen T. Romer Undergraduate Teaching and Research Award at Brown University.

Experimental study

People

Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder

9-Dec-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post:

Researchers identify brain signals associated with OCD symptoms, paving way for adaptive treatment - EurekAlert

The interventional neuroradiology market was valued at US$ 1,969.39 million in 2018 and it is projected to reach US$ 3,254.55 million in 2027; it is expected to grow at a CAGR of 5.9% from 2018 to 2027.

Interventional neuroradiology is a medical sub-specialty that utilizes minimally-invasive image based technologies and procedures for the diagnosis and treatment of various diseases of head, neck and spine. The interventional neuroradiology therapies are accomplished majorly with the help of microcatheters inserted in the groin area and, under X-ray guidance, threaded through the blood vessels leading into the brain.

Download Sample [PDF] Copy of Interventional Neuroradiology Market study at: https://www.theinsightpartners.com/sample/TIPRE00003497/

Some of the players operating in interventional neuroradiology market are, Balt Extrusion, Merit Medical Systems, Terumo Corporation, Medtronic, Penumbra, Inc., Stryker, DePuy Synthes, Boston Scientific Corporation, W. L. Gore & Associates, and MicroPort Scientific Corporation among others.

The market players have been establishing acquisitions and collaborations in the market, which enables them to hold a strong position in the market. For instance, in November, 2018, Stryker completed the acquisition of K2M Group Holdings, Inc. The acquisition aims to increase the product portfolio of Strykers spine and neurotechnology segment. The developments performed by the companies are helping the market to grow in the coming years.

The interventional neuroradiology market by product is segmented into neurovascular embolization & coiling assist devices and accessories. In 2018, the neurovascular embolization & coiling assist devices segment held a largest market share of 72.17% of the interventional neuroradiology market, by product. This segment is also expected to dominate the market in 2027 owing to increase in the number of interventional neurology procedures. The segment is also anticipated to witness the growth at a significant rate during the forecast period, 2018 to 2027.

Progressive aging population, increasing demand for minimally invasive procedures and rise in the prevalence of the cerebral aneurysm play vital role in the growth of the interventional neuroradiology market. However, the restraints such as high cost of embolization coils and dearth of skilled professionals are likely to impact the growth of the market in the forecast period.

The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide.

Download the Latest COVID-19 Analysis on Interventional Neuroradiology Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00003497

Rise in the Prevalence of the Cerebral Aneurysm to Drive Global Interventional Neuroradiology Market Growth

Neurological diseases are the disorders of the brain, spine and the nerves that connect them. There are more than 600 diseases of the nervous system, such as brain tumors, epilepsy, Parkinsons disease and stroke as well as less familiar ones such as front temporal dementia. During recent years, the prevalence of neurological disorders have increased significantly.

A cerebral aneurysm (also called an intracranial aneurysm or brain aneurysm) is a bulging, weakened area in the wall of an artery in the brain, resulting in an abnormal widening, ballooning, or bleb. Because there is a weakened spot in the aneurysm wall, there is a risk for rupture (bursting) of the aneurysm. The most common type of cerebral aneurysm is called a saccular, or berry, aneurysm, occurring in 90 percent of cerebral aneurysms. This type of aneurysm looks like a berry with a narrow stem. More than one aneurysm may be present. Two other types of cerebral aneurysms are fusiform and dissecting aneurysms. A fusiform aneurysm bulges out on all sides (circumferentially), forming a dilated artery. Fusiform aneurysms are often associated with atherosclerosis.

The prevalence of cerebral aneurysms has increased tremendously across the globe. Approximately, 30,000 people in the United States suffer from brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. The annual rate of rupture in the United States is found to be around 8 10 per 100,000 people. Hence, the rising prevalence of cerebral aneurysms is anticipated to fuel the growth of the market during the forecast period.

Order a Copy of Interventional NeuroradiologyMarket Shares, Strategies and Forecasts 2021-2027 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00003497/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone:+1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/interventional-neuroradiology-market

Read the original here:

Interventional Neuroradiology Market Revenue to Cross US$ 3254.55 million by 2027 Says, The Insight Partners - Digital Journal

COLUMBUS, Ohio, Dec. 8, 2021 /PRNewswire/ -- Avation Medical, an innovative advanced neuromodulation and digital health company pioneering closed-loop, wearable neuromodulation therapies that eliminate the need for surgery and implants, announced today the appointment of two highly experienced medical device and health care executives to its Board of Directors. The two new Board members bring a wealth of commercialization experience as the Company moves quickly to bring its first product to market.

Renee Selman,anaccomplished pharmaceutical, medical device and healthcare services senior executive and former Worldwide President, Women's Health and Urology for Ethicon, a Johnson & Johnson Company, has joined the Board as an Independent Director. Renee brings extensive global and domestic experience in the healthcare industry including commercialization of international products, market development, and strategic partnership development. Ms. Selmancurrently serves on the boards of FEMSelect and Hunterdon Medical System.

Raymond Huggenberger, a senior business leader with deep experience in innovative medical technology spanning more than 20 years of successful sales, marketing, and general management experience in highly competitive industries, has been appointed as an Independent Director. Ray previously served as the President and CEO of Inogen, Inc., and currently serves on the boards of several publicly traded medical device companies including Tactile Systems Technology, Inc. (TCMD), Inogen, Inc. (INGN) and Intricon Micromedical Technology (IIN) as well as several privately held companies. He also serves in an advisory capacity to Arboretum Ventures.

"Renee and Ray bring a wealth of strategic experience to Avation Medical which will be essential as we work to launch our category-changing, wearable and self-adjusting bladder modulation and digital health system to help the more than 40 million adults with overactive bladder (OAB) and urge incontinence that do not want invasive surgical procedures or the side effects of medications," said Jill Schiaparelli, President and CEO of Avation Medical.

"There remains an enormous need for patient-friendly, wearable neuromodulation therapy. I am honored to join the Avation Medical Board of Directors and work with the Company's talented team as we work to bring innovative technologies to the market," said Ms. Selman."Avation is a true innovator in the industry, and I look forward to supporting its ongoing work to revolutionize the science of self-adjusting, wearable neuromodulation and digital health therapies."

Mr. Huggenberger commented, "I am excited to join Avation Medical's board and work with the Company to make neuromodulation therapy surgery-free and more accessible to patients across a variety of clinical conditions. The Company's pioneering technology is a game-changer and will provide a new solution to the millions of OAB patients who desire surgery-free and drug-free treatment options."

In addition to Renee and Ray, the Board includes Dr. Thomas Shehab, Managing Partner, Arboretum Ventures; Kevin Wasserstein, Neurotechnology Innovations Management; and Jill Schiaparelli, President and CEO of Avation Medical.

About Avation MedicalAvation Medical is an innovative advanced neuromodulation and digital health company pioneering closed-loop, patient-friendly, wearable neuromodulation therapies that deliver personalized therapy based on the patient's own physiologic response.The Company's intelligent wearable therapies objectively confirm activation of the target nerve and make neuromodulation technology accessible to millions of patients across a variety of clinical applications by eliminating the need for surgery, needles and permanent implants and shifting therapy into the home environment.

The Company's wearable bladder therapy and digital health system is available for investigational use only and is not FDA cleared.

Corporate ContactJackie GerberrySenior Director, Finance[emailprotected]www.Avation.com

SOURCE Avation Medical

Read more from the original source:

Avation Medical Announces the Appointment of Industry Veterans to Board of Directors - PRNewswire

Deutsche Bank (DE:) analyst Pito Chickering maintained a Buy rating on Stryker Corporation (NYSE:) on Thursday, setting a price target of $285, which is approximately 8.08% above the present share price of $263.69.

Chickering expects Stryker Corporation to post earnings per share (EPS) of $1.17 for the fourth quarter of 2021.

The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $288.5.The analysts price targets range from a high of $305 to a low of $250.

In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $4.16 billion and a net profit of $590 million. The company's market cap is $99.47 billion.

According to TipRanks.com, Deutsche Bank analyst Pito Chickering is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 9.9% and a 47.14% success rate.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Read more here:

Deutsche Bank Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com

Robotic innovation in healthcare is becoming increasingly commonplace. From training to surgeries, research, and therapy, medical robots are in high demand. Next-generation Smart hospitals have robotics that can help reduce infections, viruses, and bacteria.

Meanwhile, 'service robots' can deliver medicines and sanitize rooms. This will help minimize human contact, particularly in vulnerable environments.

The far-reaching effects of the global pandemic highlight the need for enhanced hygiene in critical care settings. Furthermore, robotic-assisted surgery and robots used in rehab are also increasingly prevalent.

The total addressable market for healthcare robotics is vast, but predictions vary. According to one research report, the global medical robot market is expected to reach $12.7bn by 2025, up from $5.9bn in 2020 at a CAGR of 16.5%.

The most significant barrier to growth is cost. But as more prominent companies get on board, lower prices should follow increased production and R&D.

Read on to discover a selection of publicly traded companies working in the field of medical robotics.

Boston Dynamics is building a range of next-generation robots with human-like characteristics. One of these, Spot, the robotic dog, is being adapted for use in hospitals. Early in the pandemic, Spot was deployed at a Boston hospital to work as a mobile telemedicine platform to help triage patients remotely.

This led the company to open-source its work to empower external mobile robotics platforms to leverage its resources to develop help for frontline healthcare workers further.

From here, Boston Dynamics is advancing R&D into a remote vital inspection to remotely measure body temperature, respiratory rate, pulse rate, and oxygen saturation. It is also looking at robot-led disinfection using UV-C light and other technology.

Spot has since expanded into a range of robotic dogs with advanced features. Spot Enterprise can operate in remote and dangerous locations with a self-charging dock with a longer deployment time. The company has also introduced Spot Arm to help Spot open and shut valves, turn handles and pull levers, meaning it can open and close doors.

For the future of humanoid robotics, Boston Dynamics is the leader of the pack. It is owned by SoftBank Group (OTCMKTS: SFTBY) and Hyundai Motor Group (OTCMKTS: HYMTF).

Founded in 1995, Intuitive Surgical (NASDAQ: ISGR) is the most prominent medical robotics company, thanks to its Da Vinci and Ion systems. It has a $121bn market cap.

Intuitive Surgical acquired its renowned Da Vinci robotic surgical system from a Stanford University project in the nineties. The company is now operating its fourth-generation Da Vinci Surgical Systems to advance Minimally Invasive Surgery (MIS) across a broad spectrum of surgical procedures.

There are now approximately 6,335 Da Vinci surgical robot systems installed around the world.

Over the past five years, the Intuitive Surgical share price has soared:

Unfortunately for Intuitive, several of its patents are expiring, opening the doors to competition. And this comes as technological advancements in robotics are coming fast, so the space is hotting up.

Both Johnson & Johnson (NYSE: JNJ) and Medtronic (NYSE: MDT) have acquired surgical-robot start-ups, while newcomer Vicarious Surgical (NYSE: RBOT) is bringing a fresh and innovative approach to robotic surgery.

Vicarious Surgical, a company looking to shake up the robotic surgery market, recently went public via SPAC D8 Holdings Corp.

Backed by Bill Gates and Becton Dickinson, it has ambitious plans to take on some of the industry's leading players, including Intuitive Surgical, Johnson & Johnson, and Medtronic. The company aims to make abdominal surgery faster, easier, and less complex with a tiny robot that enters the patient's abdomen through a single incision. It is starting with hernia repairs.

Vicarious hopes to have its robots on the market by 2023, with a $1bn annual revenue target by 2027.

Accuray (NASDAQ: ARAY) develops, manufactures, and sells radiotherapy systems for alternative cancer treatments globally. The company uses medical robots in cancer treatments and surgeries.

The Accuray CyberKnife System is the first surgical robot to administer radiotherapy. This helps pinpoint the area to be treated, reducing the potential damage to healthy tissue.

Stryker (NYSE: SYK) is a large biotech company in the US. It operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine.

The company manufactures robotic-arm assisted surgery machines.

Stryker Mako robots assist surgeons in joint surgeries for partial and total hip and knee replacements, using 3D modeling of bone anatomy.

AVRA Medical Robotics, Inc. (OTCMKTS: AVMR) is developing a prototype surgical robotic device supporting minimal invasive surgical facial corrections. The firm also develops and commercializes intelligent medical robotic systems.

AVRA is a nano-cap stock with a $3.6m market cap.

Medtronic (NYSE: MDT) is a medical equipment company based in Ireland. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical-Surgical Portfolio, and Diabetes Operating Unit.

In 2018, Medtronic bought Mazor Robotics, which builds spine and brain surgical guidance systems for minimally invasive procedures.

The company has a $158bn market cap and offers a 2% dividend yield.

GE Healthcare (NYSE:GE) is to acquire BK Medical from private-equity firm Altaris Capital Partner. It will pay $1.45bn to extend its ultrasound business into surgical visualization. This is used to guide surgeons during minimally invasive and robotic surgeries. It also helps surgeons visualize deep tissue during procedures in neuro and abdominal surgery, and in ultrasound urology.

Many universities and private companies are also developing some incredible new robots. For instance, The University of Hertfordshire in the UK has developed a child-like robot called Kaspar, a social companion to children with autism and other communication difficulties.

Meanwhile, Xenex Disinfection Services is a company providing a pesticidal device for cleaning healthcare facilities. It offers LightStrike Germ-Zapping Robot and Disinfection Pod, which integrates into hospital cleaning operations and eliminates harmful bacteria, viruses, and spores that can cause hospital-acquired infections in the patient environment. Xenex Disinfection Services has raised over $90m in private funding.

There are several medical robotics stock options open to retail investors. But some are particularly small and speculative.

The ongoing battle against Covid-19 may continue to have a detrimental effect on elective surgeries. This could impact some medical robotics stocks short term. But once things are under control, demand for surgeries should bounce back with a vengeance.

Healthcare is rapidly changing. Advancements in technology and rising competition are bringing innovative solutions via medical robotics.

Improving patient care and outcomes is driving investment in the space.

There are fast-growing segments within the medical robotics sector

Aging populations are increasing demand for surgeries

Lack of healthcare staff raises demand for robotic solutions

Originally posted here:

Investing in Medical Robotics - Value The Markets

The general elections in Ghana which took place on December 7, 2020, unfolded successfully with fair, transparent and credible results thanks to a biometric voter management system deployed by Neurotechnology, the company said in a recent press release.

Within just a period of nine months, the companys deep learning-based MegaMatcher Automated Biometric Identification System (ABIS) helped Ghanas Electoral Commission (EC) successfully carry out voter registration, de-duplication, adjudication, final voter list generation, as well as voter verification on polling day.

Neurotech said it assisted the Ghana EC not only with the biometric technology software but with other services including onsite support in the course of the polls.

The MegaMatcher ABIS fingerprint and facial recognition solution identified 15,860 multiple registrations conducted by 7,890 unique individuals who attempted to register more than once using different identities.

The solution ensured highly accurate identification and verification of voters on polling day, making sure only legitimate voters were allowed to cast their ballot, the company stated.

We are highly satisfied with Neurotechnologys software and services, which were provided in a short timeframe nine months to be precise, from inception to completion. The staff of Neurotech were highly professional and helpful. They were responsive and accessible in that they were physically present on site throughout the duration of the exercise, said Ghana Electoral Commission Chairperson Jean Mensa.

Neurotechnology Director Irmantas Naujikas said the company was pleased to have worked with the Ghanian electoral umpire during the 2020 elections.

Ahead of the elections in Ghana last December, the government had said it procured 75 thousand biometric voter verification devices, and hoped this would ensure the quick release of results. Days after the election, the opposition claimed the electoral commission was tampering with the biometric devices used on election day.

Neurotechnology has also provided its software for de-duplication in Indias Aadhaar biometric ID program, as well as DRCs 2018 election.

ABIS | Africa | biometric identification | biometrics | deduplication | elections | Ghana | identity verification | Neurotechnology | voter registration

Excerpt from:

Neurotechnology reveals ABIS caught 15K duplicate ...

Home | Unicorn Hybrid Black

Access your brain with Unicorn Hybrid Black. Your wearable, high-quality EEG headset by g.tec neurotechnology GmbH, Austria.

Get yours

Are you a neuroscientist, an engineer, an artist or a programmer? Or simply a talented open mind who wants to do awesome stuff with brain signals and brain-computer interfaces?

Say hello to the Unicorn Hybrid Black, the wearable EEG headset. You want good data. Unicorn Hybrid Black will deliver. Let your ideas come true.

LEARN MORE

Get 100% purity in your EEG data and access to raw data and APIs for maximum development freedom. It comes without a cover which gives you total freedom of how you mount the EEG amplifier on your head.

LEARN MORE

What I like is where the Unicorn Hybrid EEG Electrodes are located: Over the motor, sensory and visual cortices - unlike most of the compact "consumer" devices that mainly register muscle activity!

Alex Ossadtchi, PhD Center for Bioelectric Interfaces, Moscow

"I'd like to thank g.tec for providing such an amazing tool along with an easy to use software package to study BCI."

Mirza Faizan, Founder & Chief Innovation Facilitator at DiscoverSTEM

The Unicorn Naked BCI is awesome. I love the flexibility it gives me for developing my own interfaces.

Craig Ades, Florida Atlantic University

I chose Unicorn Hybrid Black because its simple to use. It doesnt require much time nor knowledge about how to use it. I think everyone can learn how to use it quickly.

Maa Jazbec, University of Arts in Linz

The BR41N.IO Hackathons are great because they bring people together with such diverse backgrounds that would not otherwise have met and interacted. This cross fertilization of ideas and backgrounds is paramount to generating out-of-the-box ideas, especially for an area that is so interdisciplinary as Brain-Computer Interfaces.

Tiago Falk, Institut National de la Recherche Scientifique, Canada

Developing a students' creativity is nothing but building the right environment for them. It means having the right equipment with the right expertise in any emerging technology.

Abdelkader N. Belkacem, Ph.D., United Arab Emirates University

We have 4 Unicorn Hybrid Black headsets at University which allow many Professors to create lab exercises in small groups. They record EEG data in the course Signal Acquisition and analyse the signals in the course Processing of Biosignals. This interdisciplinary approach is important to us.

Lukas Traxler, University of Applied Sciences, Vienna

I have known g.tec medical engineering for many years and I am used to their top-quality devices. I needed an affordable, small BCI headset that delivers good EEG data quality. So, I chose Unicorn Hybrid Black for our company. We use it for developing and testing VR games. Its extremely easy to use and I can demonstrate EEG in a short time.

Robert Leeb, Mindmaze

I make digital arts in combination with light and audio animation. Since I want to develop all my tools from scratch on my own, Unicorn Hybrid Black was the perfect solution. The brain activity influences my visual arts, every time I start my visualization with the BCI, it looks differently.

Alex Guevara, Visual Artist

My EEG project Agent Unicorn would not exist without the Unicorn Brain Interface two magical forces combined!

Anouk Wipprecht, Fashion-Tech Designer

The BR41N.IO Hackathon offers a high professional level accompanied with intensive mentoring and support by the team of g.tec neurotechnology. This approach lead to astonishing results and gave the visitors of the Ars Electronica Festival some interesting insights in the many application possibilities of brain-computer interface and neurotechnology.

Gerfried Stocker, Artistic Director Ars Electronica Linz

Our students often request to learn about brain-computer interfaces because its a hot topic these days. So, we use the Unicorn Education Kit to create lab exercises for students in Biomedical Engineering and Smart Home & Assistive Technologies.In one course, we record EEG data and get into it. In another course, we process the EEG data and dive into more technical lessons.

Lukas Traxler, Professor at the University of Applied Sciences, Vienna

With the current pandemic, we needed a new approach to remotely train our graduate students on EEG data collection and analysis. With the Unicorn Education Kit, we will be able to let the students bring the EEG headset home, practice with them and thus make sure they are prepared to run their research project at the Tech3lab once we can resume the operation. In other words, the Unicorn Education Kit helps us to reduce the impact of the pandemic on our training and scientific program.

Pierre-Majorique Lger, Ph.D., Co-director Tech3Lab at HEC Montral

Unicorn Hybrid Black

Work with Unicorn Brain Interface to produce real life top-quality EEG data.

Unicorn Hybrid Black is an affordable, customizable and flexible solution that helps you quickly & thoroughly conduct your studies.

LEARN MORE

Unicorn Education Kit

Teach your students EEG, Brain-Computer Interfaces, signal acquisition, analysis & processing in the most interactive way possible.Unicorn Education Kit offers 8 headsets, user-ready applications and training material for self-study.

LEARN MORE

Unicorn Naked BCI

The new Unicorn Naked BCI gives you full flexibility in developing your own EEG headset and BCI applications with many open source modules.Develop brain-controlled VR/AR or games, build and craft your own EEG cap!

LEARN MORE

Turnkey solution

Implement Unicorn Hybrid Black into your creative process to realize unique art and science projects.

LEARN MORE

Customizable Software

You want to brain-control devices, robots or virtual reality?You love simplicity and fast control over technologies?

Unicorn Hybrid Black and its Unicorn Speller are your perfect, turnkey solutions.

LEARN MORE

Neuromarketing & Market Research

Find out what attracts you the most and unveal hidden desires with the Unicorn Blondy Check add-on.

LEARN MORE

Communication & Painting

Help ALS/COMA patients to communicate & paint whatever is on their mind. Offer a new treatment approach and help your patients to communicate with their families.

LEARN MORE

The Hardware

The Unicorn Hybrid Black is a high-quality wearable EEG-headset for brain-computer interface (BCI) applications to perfectly acquire brain waves.

LEARN MORE

The Software

The Unicorn Hybrid Black is a high-quality wearable EEG-headset for brain-computer interface (BCI) applications to perfectly acquire brain waves.

LEARN MORE

Complete Solution

The Unicorn Brain Interface is a high-quality wireless EEG-headset for brain-computer interface (BCI) applications to perfectly acquire brain waves.

buy

Learn more

Education Solution

Unicorn Education Kit includes 8 Unicorn Hybrid Black and the complete Unicorn Suite Hybrid Black software environment to make your students ready for neuroengineering.

buy

Learn more

NEUROMARKETING SOFTWARE

The software add-on for neuromarketing reasearch to rank pictures, illustrations, logos by the importance of the brain. Upload your own picture sets into the Paradigm Editor for your individual needs.

buy

Learn more

P300 SPELLER SOFTWARE

The Unicorn Speller is a spelling application for the wearable Unicorn Hybrid Black that uses the P300 paradigm and comes with Unicorn Sphero and Unicorn Painting add-ons.

buy

Learn more

Software

The Unicorn Python API enables the communication with the Unicorn Hybrid Black from Python applications. You can acquire data from Unicorn Hybrid Black devices easily without having to take care of low-level data acquisition issues.

buy

Learn more

Software

The Unicorn Simulink Interface is a library enabling the communication with the wearable Unicorn Hybrid Black from MATLAB Simulink applications. Read recorded data into Simulink and perform real-time processing.

buy

Learn more

Consumable

This set consists of 2 250 ml Unicorn Gel for Unicorn Hybrid EEG Electrodes, a syringe for gel application and 50 pieces of Unicorn Sticky Electrodes.

buy

Learn more

Quick-Start Guide, User Manual and Video Tutorials

Unicorn Suite software can be used right away or customized with development tools

We use cookies on our website. Some of them are essential, while others help us to improve this website and your experience.

Here you will find an overview of all cookies used. You can give your consent to whole categories or display further information and select certain cookies.

See more here:

Home | Unicorn Hybrid Black

Morgan Stanley (NYSE:) analyst Drew Ranieri maintained a Buy rating on Stryker Corporation (NYSE:) on Friday, setting a price target of $305, which is approximately 17.44% above the present share price of $259.7.

Ranieri expects Stryker Corporation to post earnings per share (EPS) of $1.17 for the fourth quarter of 2021.

The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $287.57.The analysts price targets range from a high of $302 to a low of $250.

In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $4.16 billion and a net profit of $590 million. The company's market cap is $97.97 billion.

According to TipRanks.com, Morgan Stanley analyst Drew Ranieri is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.9% and a 40.00% success rate.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See the original post here:

Morgan Stanley Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com